drugset / Trial / NCT00122499

A Study to Assess the Efficacy of Tadalafil to Treat Erectile Dysfunction After Radiotherapy of Prostate Cancer

NCT00122499

Phase 3 Completed Erasmus Medical Center
RandomizedCrossoverDouble-blindTreatment

Summary

This study has been designed to evaluate the efficacy and safety of a 20-mg dose of tadalafil administered "on demand" to patients with erectile dysfunction (ED) after external-beam radiotherapy (EBRT) of prostate cancer.

Timeline

Start
2003-02
Primary completion
Completion
2005-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Tadalafil Small molecule 20 mg Oral